Sunday, April 19, 2026
30.4 C
Bengaluru

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business unit. It was a scientific...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Topics

Don't Miss MedicinMan Updates

Hot this week

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

Blinkit, Zepto, Instamart: Who Will Own India’s At‑Home Diagnostics Market?

India’s diagnostics market is undergoing a quiet but profound...
spot_img

Follow Us

Popular Categories

Video Insights

spot_imgspot_img

Headlines

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business unit. It was a scientific outpost. I entered this field when...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the "Top Line": India’s domestic market at $25 billion (₹2.12 lakh...

Exclusive Articles

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the "Top Line": India’s domestic market at $25 billion (₹2.12 lakh...

Music

The Strait of Hormuz—Why Geopolitics Is Now Core to India’s Healthcare Strategy

"Those who cannot remember the past are condemned to...

Brecht Vanneste has been appointed as Managing Director of MSD India

He steps into the role with a clear mandate...

From Collapse to Catalyst: Orchid Pharma’s Innovation-Led Phoenix Rise and the AMR Challenge

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

Oracle Debacle – Midlife Reinvention is an Al Generated Orwellian Lie

A Tale of Two Truths: Severance, Up in the...

Food

From Collapse to Catalyst: Orchid Pharma’s Innovation-Led Phoenix Rise and the AMR Challenge

Opening Frame: The "Silent" Pandemic Meets Strategic Grit In the...

Oracle Debacle – Midlife Reinvention is an Al Generated Orwellian Lie

A Tale of Two Truths: Severance, Up in the...

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Samuel Paradise

Manuela Cole

Keisha Adams

George Pharell

spot_imgspot_img

Leaders Speak

Business leaders sharing their insights

K. Hariram
8 POSTS
Raja Reddy
5 POSTS